Abstract: Pharmaceutical compositions are described containing Hyaluronic Acid and Carnosine for use in the treatment and prevention of osteoarthritis (OA) and for the treatment of rheumatoid arthritis (RA).

Abstract: A comminuting device of biological material includes a casing that contains fixed cutting elements and movable cutting elements cooperating with each other to grind biological material, a collecting chamber for ground biological material, and a partition wall adjacent to the collecting chamber. The fixed and movable cutting elements are above the partition wall together with the biological material to be ground. The collecting chamber is below the partition wall. The fixed cutting elements are in the form of elongated corners that extend radially. The movable cutting elements are in the form of elongated corners that extend radially. The partition wall is provided with wall portions. Calibrated holes are provided for the passage of biological material ground by the fixed cutting elements and the movable cutting elements. The collecting chamber is in connection with the outside of the casing through at least a channel.

Abstract: Disclosed is a nanoparticle system consisting of a polymer support or substrate in the form of nanoparticles to which a hydrolase enzyme able to degrade hyaluronic acid and one or more biologically and/or pharmacologically active molecules are covalently bonded, its preparation process and its uses in the diagnostic, prognostic and therapeutic fields.

Abstract: Ester and sulfated derivatives of hyaluronic acid are described for use in the prevention and treatment of the initial stage of SARS-CoV-2 disease.

Abstract: A bio-ink for use in 3D printing, the related conjugate and the preparation process of an intermediate consisting of a bifunctional photoreactive linker are described. Said bio-inks are used for the manufacturing of constructs by 3D printing.

Abstract: A pharmaceutical composition includes a paclitaxel prodrug associated with pharmacologically acceptable diluents/excipients for use in the treatment of non-muscle invasive bladder cancer (NMIBC) by intravesical instillations according to a single weekly dose of 600 mg of the prodrug, or two weekly doses equal to a total of 1,200 mg, for 12 or 6 consecutive weeks of treatment. The paclitaxel prodrug used was prepared according to an indirect synthesis process between molecules of hyaluronic acid (HA) and paclitaxel by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and chemotherapeutic agent.

Abstract: A pharmaceutical sterile composition consisting of hyaluronic acid sodium salt and Hyaff11p50 and related use in the intravesical treatment of interstitial cystitis or Bladder Pain Syndrome (IC/BPS), of acute cystitis following bacterial infection, trauma or urolithiasis, of cystitis caused by radiation, chemotherapy, and hemorrhagic cystitis, as well as in the treatment of the bladder of patients undergoing endoscopic resection of benign or malignant bladder tumour at risk of relapse, are described.

Abstract: The present invention relates to a multilayer composite material for the treatment of wounds and lesions and to a dressing comprising said multilayer material.

Abstract: The present invention relates to a multilayer composite material for the treatment of wounds and lesions and to a dressing comprising said multilayer material.

Abstract: A slow-release medical plaster is described, based on diclofenac, specifically a medical plaster based on diclofenac sodium salt, whose formulation allows the release of the active ingredient continuously and at locally therapeutically active concentrations over 24 hours, and also the polymer adhesive matrix (PSA) for use in a medical plaster based on diclofenac sodium salt.

Abstract: An industrial synthesis process of a hyaluronic acid-paclitaxel conjugate obtained by introducing the 4-bromobutyric acid spacer/linker between the hyaluronic acid and the paclitaxel, said conjugate being characterized by a high purity, the related pharmaceutical compositions for use in the treatment of multiple cancer forms are described.

Abstract: HA-paclitaxel conjugate for use in the loco-regional treatment of the mesothelioma, i.e., the malignant pleural mesothelioma, pericardial mesothelioma and peritoneal mesothelioma, preferably malignant pleural mesothelioma, and relative pharmaceutical compositions are described.

Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 11038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.

Abstract: Disclosed is a nanoparticle system consisting of a polymer support or substrate in the form of nanoparticles to which a hydrolase enzyme able to degrade hyaluronic acid and one or more biologically and/or pharmacologically active molecules are covalently bonded, its preparation process and its uses in the diagnostic, prognostic and therapeutic fields.

Abstract: Disclosed is a nanoparticle system consisting of a polymer support or substrate in the form of nanoparticles to which a hydrolase enzyme able to degrade hyaluronic acid and one or more biologically and/or pharmacologically active molecules are covalently bonded, its preparation process and its uses in the diagnostic, prognostic and therapeutic fields.

Abstract: Disclosed are alkenylamides of sulfated hyaluronic acid and their use for the stabilisation and release of medicaments in the form of micellar suspensions which can be administered locally and/or locoregionally, in particular intra-articularly.

Abstract: The present invention concerns a process for the preparation and purification of the sodium salt of HA from the fermentation broth of Streptococcus or Bacillus or from rooster combs, the sodium salt of HA obtained and purified with said process and pharmaceutical, cosmetic and nutritional compositions comprising said sodium salt of HA.

Abstract: Pharmaceutical compositions are described comprising amide derivatives of hyaluronic acid for use in the treatment of bone mineralization in bone traumas, in particular in patients with problems of osteopenia or osteoporosis. More specifically, these compositions are used in the treatment of bone mineralization in bone fractures, in patients suffering from pathologies characterized by a T-score index lower than ?1, preferably lower than ?2.5.

Abstract: A comminuting device of biological material and relative method for comminuting and preparing cellular preparations are described.

Abstract: The present invention relates to pharmaceutical compositions comprising mixtures of a statin and a hyaluronic acid amide derivative which are useful in the treatment of inflammation and degradation of osteoarthritic joint cartilage, in particular post-traumatic osteoarthrosis and osteoarthrosis caused by physiological joint aging, and in the treatment of other joint disorders such as rheumatoid arthritis.